141 related articles for article (PubMed ID: 24436275)
1. Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels.
Gosselin R; Hawes E; Moll S; Adcock D
Am J Clin Pathol; 2014 Feb; 141(2):262-7. PubMed ID: 24436275
[TBL] [Abstract][Full Text] [Related]
2. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay.
Gosselin RC; Dwyre DM; Dager WE
Ann Pharmacother; 2013 Dec; 47(12):1635-40. PubMed ID: 24259624
[TBL] [Abstract][Full Text] [Related]
3. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
[TBL] [Abstract][Full Text] [Related]
4. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
6. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran: is there a role for coagulation assays in guiding therapy?
Brunetti L; Bandali F
Ann Pharmacother; 2013 Jun; 47(6):828-40. PubMed ID: 23673530
[TBL] [Abstract][Full Text] [Related]
8. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
Stangier J; Feuring M
Blood Coagul Fibrinolysis; 2012 Mar; 23(2):138-43. PubMed ID: 22227958
[TBL] [Abstract][Full Text] [Related]
9. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
11. Determination of dabigatran in human plasma samples.
Harenberg J; Giese C; Marx S; Krämer R
Semin Thromb Hemost; 2012 Feb; 38(1):16-22. PubMed ID: 22314599
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.
Antovic JP; Skeppholm M; Eintrei J; Boija EE; Söderblom L; Norberg EM; Onelöv L; Rönquist-Nii Y; Pohanka A; Beck O; Hjemdahl P; Malmström RE
Eur J Clin Pharmacol; 2013 Nov; 69(11):1875-81. PubMed ID: 23784008
[TBL] [Abstract][Full Text] [Related]
13. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
[TBL] [Abstract][Full Text] [Related]
15. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
van Ryn J; Grottke O; Spronk H
Clin Lab Med; 2014 Sep; 34(3):479-501. PubMed ID: 25168938
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations.
Jaffer IH; Chan N; Roberts R; Fredenburgh JC; Eikelboom JW; Weitz JI
J Thromb Haemost; 2017 Dec; 15(12):2377-2387. PubMed ID: 28976630
[TBL] [Abstract][Full Text] [Related]
17. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
Douxfils J; Dogné JM; Mullier F; Chatelain B; Rönquist-Nii Y; Malmström RE; Hjemdahl P
Thromb Haemost; 2013 Sep; 110(3):543-9. PubMed ID: 23783171
[TBL] [Abstract][Full Text] [Related]
18. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
19. The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters.
Green L; Lawrie AS; Patel R; Stephens RC; Mackie IJ; Chitolie A; Haddad FS; Machin SJ
Thromb Res; 2012 Nov; 130(5):775-9. PubMed ID: 22245224
[TBL] [Abstract][Full Text] [Related]
20. Idarucizumab for Dabigatran Reversal.
Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
